Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor used to treat type 2 diabetes.
ChEBI: Ertugliflozin is a diarylmethane.
Ertugliflozin is a medication prescribed by veterinarians to help control insulin (blood sugar) levels in horses and ponies with insulin dysregulation (ID), equine metabolic syndrome (EMS), refractory hyperinsulinemia (high blood sugar), and hyperinsulinemic-associated laminitis (HAL), especially for horses that don't respond to changes in diet or other accepted management practices for metabolic syndromes. Ertugliflozin is not FDA-approved for equine use. It falls into the sodium-glucose co-transport-2 (SGLT2) inhibitors category and is administered orally at 0.05?mg/kg once daily for at least 30?days.
Ertugliflozin works by inhibiting the SGLT2 protein, which aids in the reabsorption of glucose in the kidneys, leading to excretion of more glucose through urine. Once daily doses of ertugliflozin have been shown to: Lower blood sugar levels, Correct insulin to normal or near-normal levels, and Reduce abnormal fat pads.
